Induction TPF did not improve three-year PFS over adjuvant PF in locally advanced NPC
Three-year PFS was 79.0% with induction TPF versus 74.5% with adjuvant PF, with substantially different toxicity profiles.
Tag
high relevance
Proton breast radiotherapy caused more acute dermatitis than photons in randomized DBCG substudy
Grade 2–3 dermatitis reached 71% with protons versus 20% with photons, but resolved within weeks and other acute toxicity was similar.
Cervical cancer advanced by one stage approximately every 8.6 weeks before radiotherapy
Cervical cancer stage progression was estimated every 8.6 weeks of treatment delay and was faster among women living with HIV.
Five-fraction prostate and pelvic SABR showed durable control with low late toxicity
Five weekly SABR fractions to prostate and pelvic nodes produced 10.5% five-year biochemical failure with low persistent gastrointestinal and urinary toxicity.
Updated ASTRO guideline expands radiation therapy across pancreatic cancer settings
ASTRO expands radiation therapy recommendations across locally advanced, recurrent and oligometastatic pancreatic cancer, with new guidance on dose escalation and adaptation.
AI biomarker substantially reduced planned ADT use in intermediate-risk prostate cancer
ASTuTE biomarker testing changed 27.5% of shared decisions and reduced planned short-term ADT use from 37% to 12.5%.
Six-fraction chemoradiation worsened survival in newly diagnosed glioblastoma
Six-fraction chemoradiation shortened median survival from 21 to 13 months and substantially increased radiation necrosis compared with standard treatment.
SUPREMO radiotherapy modestly worsened chest wall symptoms without broader quality-of-life loss
EXCERPT At five years, chest wall radiotherapy modestly worsened local symptoms but did not significantly affect overall quality of life or major functional domains.
Most European proton candidates still face critical access shortages
More than 56,000 theoretically eligible European patients lived in areas with no proton access or critical capacity shortages in 2025.
Euro-EWING99 long-term analysis defines outcomes in 3,395 patients with Ewing sarcoma
Five-year progression-free and overall survival were 55.4% and 64.6%, with metastatic status and histologic response remaining major prognostic factors.
Escalating esophageal chemoradiotherapy from 50.4 to 60 Gy provided no benefit
Three-year outcomes numerically favored 50.4 Gy over 60 Gy, while multivariable analysis found no significant survival advantage from either dose.
Re-irradiation was associated with longer survival after pediatric diffuse midline glioma progression
COMPPARE enrolled 2,524 patients from 51 institutions in 52 months, with Black participation reaching 16% of the cohort.
Omitted guideline-recommended sectors drove local failure after sacral SBRT
Seventy-three percent of failures after nonadherent sacral contouring involved sectors that guidelines recommended including in the clinical target volume.
Pelvic insufficiency fractures affected nearly one-third after gynecologic IMRT
Pelvic insufficiency fractures occurred in 29.2% of patients, with postmenopause and elevated baseline t-PINP independently predicting risk.
Earlier lung cancer diagnosis exposed major delays in curative radiotherapy access
In 2024, only 3.2% of English patients began curative radiotherapy within the 49-day target despite rapidly rising demand.